Nature Reviews Drug Discovery contents September 2016 Volume 15 Number 9 pp 589-660

If you are unable to see the message below, click here to view.

Advertisement
Free Naturejobs Career Expo London Registration is now open for the free Naturejobs Career Expo London on September 16, 2016. Be sure to attend this special 10 year anniversary of the London science career fair for your chance to meet employers face-to-face, attend all conferences and workshops, take part in our photo booth fun, win amazing prizes and so much more!  Register Free today!
TABLE OF CONTENTS
September 2016 Volume 15 Number 9		Advertisement
Impact Factor 47.120 *	In this issue Comment News and Analysis Research Highlights Reviews Also this month  Featured article: Twenty years on: the impact of fragments on drug discovery Daniel A. Erlanson, Stephen W. Fesik, Roderick E. Hubbard, Wolfgang Jahnke & Harren Jhoti	BJC collections: Cancer Immunotherapy Immunotherapies have revolutionised therapy for some cancers. In parallel with therapeutic trials, many other mechanisms and pathways are being investigated in optimising these treatments.  Access this collection from British Journal of Cancer - free online for six months: Produced with support from: EMD Serono
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Emerging Paradigms in Drug Discovery & Chemical Biology October 25, 2016 This one-day symposium will cover on-target and off-target identification of drug-protein interactions in neuroscience, cancer, the ubiquitin proteasome system, GPCRs, and protein lipidation mechanisms. Register here. Poster Abstract Deadline Sept. 2.
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Open for Submissions  npj Precision Oncology is a new open access, online-only, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine. The journal is part of the Nature Partner Journals series and published in partnership with The Hormel Institute, University of Minnesota.  Explore the benefits of submitting your manuscript >>
Advertisement
The 4th Helmholtz-Nature Medicine DIABETES CONFERENCE  Accepting abstracts on type 2 diabetes research! September 18-20, 2016 | Lenbach Palais, Munich, Germany  REGISTER NOW!
Comment: Accelerating global innovation to address antibacterial resistance: introducing CARB-X Kevin Outterson, John H. Rex, Tim Jinks, Peter Jackson, John Hallinan, Steve Karp, Deborah T. Hung, Francois Franceschi, Tyler Merkeley, Christopher Houchens, Dennis M. Dixon, Michael G. Kurilla, Rosemarie Aurigemma & Joseph Larsen p589 | doi:10.1038/nrd.2016.155 A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public-private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials. Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure Asher Mullard p591 | doi:10.1038/nrd.2016.176 AbbVie, Bristol-Myers Squibb, Genentech, Janssen and Merck & Co. have all advanced anti-tau candidates into Phase I trials in the hunt for drugs that can modify the course of Alzheimer disease. PDF
Sickle cell solutions in sight Katie Kingwell p593 | doi:10.1038/nrd.2016.177 New targets, new drug modalities and new business strategies are drawing long-awaited attention to sickle cell disease. PDF
NEWS IN BRIEF Leading microbiome-based therapeutic falters in Phase II trial Asher Mullard p595 | doi:10.1038/nrd.2016.181 PDF
mRNA-based drug approaches Phase I milestone Asher Mullard p595 | doi:10.1038/nrd.2016.182 PDF
EMA rewrites Phase I guidelines in aftermath of FAAH tragedy Asher Mullard p595 | doi:10.1038/nrd.2016.183 PDF
BIOBUSINESS BRIEFS Trial watch: Impact of genetically supported target selection on R&D productivity Mark R. Hurle, Matthew R. Nelson, Pankaj Agarwal & Lon R. Cardon p596 | doi:10.1038/nrd.2016.164 PDF
BIOBUSINESS BRIEFS Deal watch: Galderma pursues 'itchy cytokine' by licensing antibody from Roche's Chugai Megan Cully p597 | doi:10.1038/nrd.2016.165 PDF
AN AUDIENCE WITH Melissa Paoloni p598 | doi:10.1038/nrd.2016.174 Melissa Paoloni, an architect of the I-SPY 2 trial at QuantumLeap Healthcare Collaborative, discusses the evolution of one of the first adaptive, umbrella trials. PDF
FROM THE ANALYST'S COUCH The bladder cancer drug market Khurram Nawaz & Rachel M. Webster p599 | doi:10.1038/nrd.2016.141 Traditional cytotoxic chemotherapies have been the mainstay of treatment for bladder cancer for decades, but targeted biologics are now becoming available. This article analyses the late-stage pipeline for bladder cancer and the impact of new drugs in this rapidly growing market. PDF
RESEARCH HIGHLIGHTS Top Metabolic disease: Leptin sensitizer reverses obesity p601 | doi:10.1038/nrd.2016.166 PDF Cardiovascular disease: Reactivating cellular rubbish removal ameliorates atherosclerosis p602 | doi:10.1038/nrd.2016.171 PDF Receptor pharmacology: The many faces of G protein-coupled receptors p602 | doi:10.1038/nrd.2016.179 PDF Autoimmune diseases: CAR-T cells take aim at autoimmunity p603 | doi:10.1038/nrd.2016.180 PDF Antibacterial drugs: Nosing around for new antibiotics p604 | doi:10.1038/nrd.2016.170 PDF IN BRIEF Ageing: Improving muscle function | Infectious disease: 3D structure of Zika virus protease | Fungal infection: Protecting from Candida albicans PDF Drug Discovery JOBS of the week Faculty Positions- Tenure Track University of Pittsburgh Postdoctoral Fellows Dana-Farber Cancer Institute (DFCI) More Science jobs from Drug Discovery EVENT Equivalence of Complex Drug Products: Scientific and Regulatory Challenges 09.11.16 New York, USA More science events from
Advertisement
Nature Plants is now accepting submissions in all areas of plant science. Do you have something in the pipeline? Find out how to submit in the Guide to Authors. Submit your research.
REVIEWS		Top
Twenty years on: the impact of fragments on drug discovery Daniel A. Erlanson, Stephen W. Fesik, Roderick E. Hubbard, Wolfgang Jahnke & Harren Jhoti p605 | doi:10.1038/nrd.2016.109 Fragment-based methods have made substantial contributions to drug discovery in the past 20 years, particularly for challenging targets. Erlanson and colleagues discuss progress in the field, key aspects such as the design of fragment libraries and the choice of screening technique, and how current challenges in fragment-based drug discovery might be overcome. Abstract | Full Text | PDF
Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease Robert G. Gourdie, Stefanie Dimmeler & Peter Kohl p620 | doi:10.1038/nrd.2016.89 The focus of cardiovascular research has changed over the decades, and non-myocytes, including fibroblasts, are becoming increasingly central to our understanding of cardiac function. Kohl and colleagues discuss cardiac fibroblasts, their origins and their expanding roles in homeostasis and tissue repair, and highlight opportunities for therapeutic intervention. Abstract | Full Text | PDF
Targeting adipose tissue in the treatment of obesity-associated diabetes Christine M. Kusminski, Perry E. Bickel & Philipp E. Scherer p639 | doi:10.1038/nrd.2016.75 Adipose tissue may become severely dysfunctional during obesity, resulting in disrupted metabolic homeostasis and ultimately type 2 diabetes. Here, Scherer and colleagues provide an overview of adipose tissue development, function and homeostasis, focusing on emerging potential strategies for targeting this organ in the treatment of obesity-associated diabetes. Abstract | Full Text | PDF
Advertisement
nature.com webcasts Springer Nature presents a custom webcast on: Accelerated biophysical characterization and screening of biologics using array surface plasmon resonance imaging Thursday September 15, 2016 8.30AM PDT, 11.30AM EDT, 4.30PM BST, 5.30PM CEST Register for the webcast and live Q&A session Sponsored by: Wasatch Microfluidics Inc.
Corrigendum: Remyelination researchers regroup after proof-of-concept setback in multiple sclerosis Asher Mullard p660 | doi:10.1038/nrd.2016.172 Full Text | PDF
Corrigendum: Oncolytic viruses: a new class of immunotherapy drugs Howard L. Kaufman, Frederick J. Kohlhapp & Andrew Zloza p660 | doi:10.1038/nrd.2016.178 Full Text | PDF
Advertisement
An open access journal dedicated to highlighting the most important scientific advances in Parkinson's disease research, spanning the motor and non-motor disorders of Parkinson's disease. Part of the Nature Partner Journals series, npj Parkinson's Disease is published in partnership with the Parkinson's Disease Foundation.  Open for submissions
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2015 Journal Citation Report (Thomson Reuters, 2015)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.